U.S. Oil and Gas Stock News

SKYX Platforms (SKYX) closed out FY 2025 with Q4 revenue of about US$24.9 million, a basic EPS loss of US$0.07, and a net income loss of roughly US$8.2 million, while the trailing twelve months showed revenue of about US$92.0 million against a net loss of around US$34.5 million and basic EPS of US$0.32 in losses. Over recent quarters the company has seen revenue move from roughly US$23.7 million in Q4 2024 to US$24.9 million in Q4 2025. Quarterly basic EPS losses shifted from about US$0.11 to...

If you are wondering whether VinFast Auto's current share price really reflects what the business is worth, you are not alone. That is exactly what this valuation focused review will tackle. The stock recently closed at US$3.39, with returns of 18.5% over 7 days, 2.7% over 30 days, 0.3% year to date and 0.0% over the last year, alongside a 67.0% decline over 3 years. Recent headlines around VinFast Auto have continued to keep the company on investors' radar and have added fresh context to...

If you are wondering whether New York Times at around US$82.79 is attractively priced or already reflecting high expectations, it helps to break the story down into what the recent share price is really telling you. The stock has delivered returns of 2.2% over the last 7 days, 7.0% over the last 30 days, 18.6% year to date, 71.1% over 1 year, 120.2% over 3 years, and 72.4% over 5 years. This puts recent performance front and center for anyone thinking about value and risk. Recent news around...

Insmed recently reported positive topline Phase 3b ENCORE results showing that adding once-daily ARIKAYCE to standard multidrug therapy improved respiratory symptoms and culture conversion rates in largely treatment-naïve MAC lung disease patients, with a safety profile consistent with prior experience. The company now plans supplemental regulatory filings in the U.S. and Japan in the second half of 2026, aiming to expand ARIKAYCE’s label from a refractory niche into the much larger...

SM Energy (SM) has drawn investor attention after a strong share price move over the past month, with the stock up about 48%. This has prompted closer scrutiny of how its fundamentals align with recent market interest. See our latest analysis for SM Energy. Beyond the recent 48.4% 30 day share price return and the latest close at $32.72, the 90 day share price return of 76.8% and 1 year total shareholder return of 16.4% point to momentum that has built over time rather than appearing...

If you are wondering whether DorianG's current share price reflects its true value, you are not alone. This article is built to help you think that through clearly. DorianG trades at US$33.35, with returns of 1.7% over 7 days, a 7.8% decline over 30 days, 34.7% year to date and 61.8% over the last year. This naturally raises questions about what is already priced in and what is not. Recent coverage of DorianG has focused on its share price performance and how investors are reacting to the...

If you are wondering whether Dow's recent run makes it overpriced or still attractive, its current valuation story is worth a closer look before you decide what to do next. The share price sits at US$40.82, with returns of 11.4% over 7 days, 36.0% over 30 days, 68.2% year to date and 26.8% over the past year. This compares with weaker 3 year and 5 year returns of 11.0% and 17.0% declines. These moves have come as Dow remains in focus for investors following ongoing attention on the broader...

How PACCAR Stock Has Been Trading Recently PACCAR (PCAR) has been relatively steady in recent months, with a last close of US$112.75. The stock shows a 1 day return of 2.24%, a 7 day gain of 1.34%, and a month decline of 9.50%. Over the past 3 months, PACCAR has a 0.86% total return, while year to date performance stands at 1.07%. Longer term, the stock shows a 19.33% 1 year total return and gains over 3 and 5 years. See our latest analysis for PACCAR. The recent 9.5% 1 month share price...

If you are wondering whether MongoDB's current share price reflects its true worth, it helps to break the story into what the market has done, what has been happening around the company, and how that ties back to valuation. The stock closed at US$235.51, with a 9.8% decline over the last 7 days, a 25.2% decline over the last 30 days, and a 41.1% decline year to date. This comes even while the 1 year return sits at 32.3% and the 3 year return at 1.0%, compared to a 5 year return of an 18.9%...

Laureate Education recently reported a strong quarter, with revenue and EPS ahead of analyst expectations, continued investment in new campuses and digital and AI capabilities, and over US$200 million returned to shareholders via share repurchases, while CFO Richard M. Buskirk sold 61,803 shares but retained the majority of his stake. Despite delivering the fastest revenue growth among peers and emphasizing ongoing business momentum, Laureate Education issued the weakest full-year guidance...

Investor Day plan and proposed rebrand put Bladex in focus Banco Latinoamericano de Comercio Exterior S. A (BLX) has moved into the spotlight after its 2026 Investor Day, where management outlined a 2030 plan to build a more transactional regional trade banking platform. The bank also plans to ask shareholders at the April 21, 2026 AGM to approve a name change to Bladex Inc. It will gradually roll out transactional services aimed at growing deposits, payments activity, and fee income. See our...

Cadre Holdings (NYSE:CDRE) has agreed to acquire Alien Gear Holsters through a court supervised bankruptcy auction. The deal remains subject to court and regulatory approvals before closing. Alien Gear Holsters is known for its holster products and direct to consumer sales channels. For investors watching NYSE:CDRE, the move adds a well known holster brand to Cadre Holdings' existing portfolio of safety and protection equipment. Alien Gear Holsters brings an established consumer following...

Stock performance snapshot Arcus Biosciences (RCUS) has drawn investor attention after recent trading left the stock near US$20.28, with returns showing mixed moves over the past week, month and past 3 months. See our latest analysis for Arcus Biosciences. While the recent 1 day share price return of a 4.38% decline and 7 day share price return of a 6.28% decline show pressure at around US$20.28, the 1 year total shareholder return of 148.23% points to strong longer term momentum despite...

Hoyne Bancorp (HYNE) has just posted its FY 2025 figures with third quarter revenue at roughly US$3.5 million and net income at about US$0.1 million, set against trailing 12 month revenue of around US$13.2 million and a loss of roughly US$0.4 million. Over the last few reported periods, the bank has seen revenue move from about US$2.5 million in Q3 2024 to roughly US$3.5 million in Q3 2025, while TTM revenue shifted from around US$10.3 million to about US$13.2 million. This provides a clearer...

Recent share performance and business snapshot Appian (APPN) has drawn investor attention after a period of weaker share performance. The stock has shown negative returns over the past week, month and past 3 months, and a 1 year total return decline of 21%. The company runs The Appian Platform, an automation and low code software offering used across industries such as financial services, government, life sciences and insurance. Its operations are supported by cloud subscriptions, licenses...

If you are wondering whether Rockwell Automation at around US$351.50 is priced for opportunity or already fully valued, the starting point is understanding what the current market price is actually reflecting. The stock has seen mixed recent returns, with a 1% decline over the last 7 days and a 12.6% decline over the last 30 days, while still showing 38.0% over 1 year, 26.1% over 3 years and 45.2% over 5 years. Recent coverage has focused on Rockwell Automation's role in industrial...

Atlassian (NasdaqGS:TEAM) plans to cut about 1,600 roles, roughly 10% of its workforce, as part of a broad restructuring. The company is realigning operations around artificial intelligence and larger enterprise customers, with meaningful restructuring costs expected. The move comes during a period of weak share price performance and heightened focus on efficiency across the software sector. For investors tracking NasdaqGS:TEAM, this restructuring lands against a difficult share price...

In March 2026, KE Holdings Inc. reported weaker fourth-quarter and full-year 2025 earnings, with net income falling year-on-year despite slightly higher annual revenue, while also announcing a reduced final cash dividend of US$0.092 per ordinary share (US$0.276 per ADS) and completing a US$2.55 billion share repurchase program. At the same time, the company’s removal from the FTSE All-World Index for its NYSE listing and inclusion via its Hong Kong listing, combined with negative free cash...

If you are wondering whether Planet Fitness at around US$73.80 is a bargain, a fair deal, or still looks expensive, you are asking the right question before making any move. The stock has seen a 0.7% slip over the last 7 days, a 7.8% decline over the past month, and is down 32.7% year to date and 23.3% over the last year, which can change how the market views its potential and its risks. These price moves sit against a backdrop of ongoing attention on Planet Fitness's position in the fitness...

United Security Bancshares (UBFO) has wrapped up FY 2025 with fourth quarter revenue of US$13.1 million and EPS of US$0.20, alongside trailing 12 month revenue of US$48.3 million and EPS of US$0.71. These figures sit against a five year earnings growth rate of 8.5% per year and a negative one year earnings growth figure. Over recent periods the company has seen revenue move from US$48.6 million and EPS of US$0.86 on a trailing 12 month basis in late 2024 to the latest trailing totals of...

Understanding American Healthcare REIT after recent share performance American Healthcare REIT (AHR) has come onto investors’ radar after recent share performance, with the stock showing a 0.6% decline over the past day and a 2.0% decline over the past week. See our latest analysis for American Healthcare REIT. The recent 10.9% 1-month share price decline has cooled the strong 1-year total shareholder return of 59.0%, so momentum appears to be fading in the short term even after a solid...

IQVIA Holdings (IQV) has put artificial intelligence at the center of its story by launching IQVIA.ai in collaboration with NVIDIA. The goal is to embed agentic AI directly into life sciences workflows across clinical, commercial and real-world applications. See our latest analysis for IQVIA Holdings. Despite the IQVIA.ai launch and recent broker upgrades, the share price is US$163.85 after a 1 day share price return of a 3.28% decline and a 90 day share price return of a 27.79% decline,...

Cigna Group Foundation released its 2025 Improving Veteran Mental Health Impact Report, outlining progress in supporting veteran mental health. The initiative has aided more than 8,000 veterans through expanded access to stable housing and integrated support services. Over 20 nonprofit partners across multiple states are involved in delivering housing, counseling, and related support. Cigna Group (NYSE:CI), trading at $261.96 at the last close, is drawing attention for its work in veteran...

Wondering if General Electric at around US$282 per share still offers value, or if most of the opportunity has already played out. The stock has pulled back recently, with a 1.4% decline over the last week and a 17.5% decline over the last month, even though the 1 year return sits at 42.2% and the 3 year return is very large. Recent coverage has focused on General Electric's position within capital goods and Aerospace & Defense, as investors reassess what the latest share price moves say...